title: Cardiac 82Rubidium PET/CT: initial European experience.
abstract: OBJECTIVE
  Myocardial perfusion with PET/CT has advantages over conventional SPECT. We describe our initial European experience using (82)Rubidium-PET/CT, as part of a clinical myocardial perfusion service.
  
  
  METHODS
  We studied the first 100 patients (64 male; 36 female, mean age = 60: SD +/-12.5y, mean body mass index = 30: SD +/-6.9kg/m( 2 )) who underwent (82)Rubidium cardiac PET/CT in our institution. Thirty patients had recently undergone coronary angiography. Patients underwent imaging during adenosine infusion and at rest. Images were acquired over 5 minutes using a GE-PET/CT instrument. Image quality was described as good, adequate or inadequate. Images were reported patient-by-patient by a minimum of five nuclear medicine physicians. A segment-by-segment analysis (17-segment model) was also performed.
  
  
  RESULTS
  Image quality was good in 77%, adequate 23% and inadequate 0%. There was no statistical difference in image quality between obese and non-obese patients (Fisher's exact test, p = 0.2864). 59% had normal perfusion studies, 29% had inducible ischaemia, 12% had myocardial infarction (11% with super added ischaemia). There was reduced (82)Rubidium uptake in 132/1700 segments during stress. There was reduced (82)Rubidium uptake at rest in 42/1700 segments. The (82)Rubidium PET/CT findings were consistent with the angiographic findings in 28/30 cases.
  
  
  CONCLUSIONS
  We show that, even from initial use of (82)Rubidium, it is possible to perform myocardial perfusion studies quickly with good image quality, even in the obese. The PET findings correlated well in the third of the cases where angiography was available. As such, (82)Rubidium cardiac PET/CT is likely to be an exciting addition to the European nuclear physician/ cardiologist's radionuclide imaging arsenal.
authors.affiliation: Institute of Nuclear Medicine, University College London, T-5 235 Euston Road, London, UK. drashleygroves@hotmail.com
authors.forename: Ashley M
authors.initials: AM
authors.lastname: Groves
authors.forename: Marie-Elsya
authors.initials: ME
authors.lastname: Speechly-Dick
authors.forename: John C
authors.initials: JC
authors.lastname: Dickson
authors.forename: Irfan
authors.initials: I
authors.lastname: Kayani
authors.forename: Raymondo
authors.initials: R
authors.lastname: Endozo
authors.forename: Patty
authors.initials: P
authors.lastname: Blanchard
authors.forename: Manu
authors.initials: M
authors.lastname: Shastry
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Prvulovich
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Waddington
authors.forename: Simona
authors.initials: S
authors.lastname: Ben-Haim
authors.forename: Jamshed B
authors.initials: JB
authors.lastname: Bomanji
authors.forename: Jean R
authors.initials: JR
authors.lastname: McEwan
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Ell
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging*; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D005060:Europe; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D049268:Positron-Emission Tomography / Q000379:methods* / Q000639:trends; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012414:Rubidium Radioisotopes; D012680:Sensitivity and Specificity; D013382:Subtraction Technique; D014057:Tomography, X-Ray Computed / Q000379:methods*; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000209:etiology
chemical_list: D019275:Radiopharmaceuticals; D012414:Rubidium Radioisotopes